Status:

COMPLETED

Reducing the Risk of Drug-Induced QT Interval Lengthening in Women

Lead Sponsor:

Indiana University

Collaborating Sponsors:

American Heart Association

Purdue University

Conditions:

Long QT Syndrome

Abnormalities, Drug-Induced

Eligibility:

FEMALE

21+ years

Phase:

PHASE4

Brief Summary

This research will determine if oral progesterone attenuates drug-induced QT interval lengthening in a) Postmenopausal women 50 years of age or older, and b) Premenopausal women studied during the ovu...

Detailed Description

Torsades de pointes (TdP) is a catastrophic arrhythmia associated with corrected QT (QTc) interval prolongation, which can be induced by \> 150 commonly prescribed drugs. TdP risk is higher in women a...

Eligibility Criteria

Inclusion

  • Postmenopausal women:
  • 50 years of age or older
  • No menstrual periods for 365 days or longer
  • Premenopausal women:
  • \- 21-40 years of age

Exclusion

  • History of breast, uterine or ovarian cancer
  • History of hysterectomy and/or ovariectomy
  • Weight \> 135 kg
  • Serum K+ \< 3.6 mEq/L;
  • Serum Mg2+ \< 1.8 mg/dL;
  • Hematocrit \< 26%;
  • Hepatic transaminases \> 3x upper limit of normal;
  • Baseline Bazett's-corrected QT interval \> 450 ms
  • Taking hormone replacement therapy
  • Diagnosis of heart failure
  • Symptoms associated with heart failure:
  • Pitting edema \> 2+
  • Crackles or rales on lung auscultation
  • S3 or S4 heart sounds
  • Unable to climb at least 2 flights of stairs without becoming short of breath
  • Current ECG rhythm of atrial fibrillation or other tachyarrhythmia
  • Family or personal history of long-QT syndrome or sudden cardiac death not associated with acute myocardial infarction
  • Concomitant use of any QTc interval-prolonging drug.
  • Permanently paced ventricular rhythm
  • Pregnancy
  • Using any hormonal contraceptives \[oral contraceptives, hormone-secreting intrauterine devices (IUDs), hormonal implants\]

Key Trial Info

Start Date :

March 26 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 23 2024

Estimated Enrollment :

27 Patients enrolled

Trial Details

Trial ID

NCT03834883

Start Date

March 26 2019

End Date

May 23 2024

Last Update

July 1 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Indiana University

Indianapolis, Indiana, United States, 46202